From Discovery to Patients: an Integrated Service for ADC Development by Lonza and Synaffix

This Lonza white paper explains how Synaffix technology and Lonza’s integrated ADC development services can help drug developers move antibody-drug conjugates (ADCs) from discovery to clinical development faster. It focuses on improving ADC stability, reducing toxicity, simplifying manufacturing and supply chains, and accelerating the path to an IND application.

• Stable, site-specific conjugation: GlycoConnect ™ enables site-specific ADC conjugation without antibody engineering, helping improve stability and therapeutic performance.
• Optimized ADC design: Lonza helps select and evaluate the right antibody, linker, payload and drug-to-antibody ratio (DAR) to develop promising ADC candidates.
• Fast DNA-to-IND pathway: The Ibex ® Design ADC Program aims to accelerate development from DNA to IND in 15 months, including a toxicology drug-substance batch in about 8 months.
• End-to-end support: Lonza integrates antibody production, payload-linker supply, conjugation, drug substance, fill/finish and supply-chain management through one platform.